Kornimate/medical-research-clean huggingface dataset:
postconditioning in the treatment of acute st-segment elevation myocardial infarction

Conditions: ST-segment Myocardial Infarction

Summary: standard treatment of patients with acute st-segment elevation myocardial infarction consist of acute re-opening of the occluded coronary artery (primary pci). despite successful treatment of the epicardial vessel reperfusion is sometimes inadequate leading to large final infarct sizes. this phenomenon is known as the reperfusion injury. several animal studies have indicated that graded re-opening of the artery may limit tissue damage. generally this is referred to as mechanical postconditioning. the study investigates the effect on final infarct size evaluated by magnetic resonance scan of postconditioning of st-segment elevation myocardial infarctions. mechanical postconditioning is performed by means of several balloon inflations in the injured vessel following its acute re-opening.

please see above

Eligibility criteria:
inclusion criteria: * patients more than 18 years * stemi \< 12 hours * timi 0-1 in infarct related artery exclusion criteria: * multivessel disease (stenoses in non-infarct related arteries \>70%) * cardiogenic shock * left main occlusions * lesions that cannot be treated with stents * previous cabg * pregnancy * severe renal insufficiency * previous extensive q-wave infarction * lbbb
testing of a mobile web app to decrease posttraumatic stress symptoms in women after sexual assault

Conditions: Posttraumatic Stress Disorder

Summary: interventions are available to all adult women sexual assault survivors to reduce the risk of pregnancy and sexually transmitted infection, yet no interventions are provided to reduce posttraumatic stress. this pilot study tests the ability of a smartphone-based web app to prevent and reduce posttraumatic stress in women sexual assault survivors.


Eligibility criteria:
inclusion criteria: * present for emergency care within 72 hours of sexual assault * receive a sexual assault nurse examiner (sane) exam * alert and oriented exclusion criteria: * unable to consent due to intoxication, serious injury preventing ability to hear, speak, or see to consent, or other causes * prisoners * pregnant women * women living with assailant who plan to continue living with assailant * women with fractures from the assault * admitted patients * women who do not have a smartphone with continuous service for the past 12 months * inability to read and speak english * no mailing address * sane exam took place \>72 hours ago * patient previously enrolled in the study

Keywords: posttraumatic stress disorder anxiety sensitivity chronic pain sexual assault
impact of tripolar radiofrequency on acne scar

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic; Scar; Radiofrequency

Summary: the aim of this study is to investigate the therapeutic efficacy of tripolar radiofrequency on acne scar

acne scarring is a very troublesome complication associated with acne and is reported in as high as 95% of the patients, sometimes even with proper and prompt treatment. the visible depressed scars have been known to have a negative impact on patient's psychological well-being and quality of life. post acne scarring can pose as a risk factor for depression, anxiety, and even suicide (villani, 2020). there are a multitude of treatment options that are traditionally used for the treatment of acne scars including many ablative and non-ablative methods (dogra, 2014). furth more, the need of this study is developed from the lack in quantitative knowledge and information in the published studies which investigate the effect of tripollar rf this study will be designed to provide guidelines about the effect tripollar radiofrequency on acne scars.

Eligibility criteria:
inclusion criteria: * forty patients having acne scar, from both genders their ages will be ranged from 20 to 40 years old * both genders will participate in this study as the following distribution 17 male and 23 female. * they diagnosed as acne scar by their physicians and referred for physical therapy management. * medically and psychologically stable patients. * all patients will approve and sign a consent form before starting the program which will include the purpose, natures and potential risks of the study which will be explained to all patients exclusion criteria: * patients who suffer from hypertrophic and/or keloidal scars and a skin condition in the area of acne scars that would interfere with study procedures (e.g., plaque psoriasis, tattoo, birthmark, facial hair). * patients with medical red flags as severe psychiatric disorder or cognitive deficits. * medically unstable and uncooperative patients. * untreated and active/ongoing acne vulgaris. * immunocompromised status. * history of skin cancer. * recurrent herpes viral infection. * pregnancy or breastfeeding status. * females take contraceptive pills * hormonal disturbance
a study of controlled lactulose withdrawal

Conditions: Hepatic Encephalopathy

Summary: after resolution of the initial episode of hepatic encephalopathy (he), lactulose is routinely continued indefinitely as maintenance therapy. although widely used for this indication, lactulose has never been shown in randomized, controlled trials to be effective for preventing exacerbations of he. indeed, lactulose was found to be ineffective at preventing he when administered prophylactically to patients undergoing portosystemic shunt insertion. while some patients may be lactulose dependent following an initial episode of he, it is likely that most could have their lactulose discontinued with no adverse consequences. this goal is worth pursuing because lactulose is not innocuous. it has an unpleasant taste, and it routinely produces gastrointestinal symptoms, including bloating, gas and diarrhea. in high doses it can cause incontinence, dehydration and electrolyte derangements. patients universally dislike taking lactulose and often are noncompliant with treatment. a recent trial showed that patients on lactulose had a substantial risk of hospital admissions due to lactulose-related complications and treatment non-compliance.

in this pilot study we propose to perform controlled lactulose withdrawal in selected patients with he whose initial presentation follows a clearly defined, reversible precipitating event or those with stable, chronic he. we hypothesize that a majority of these patients can be withdrawn from daily lactulose therapy without deterioration of cognitive function, and that lactulose withdrawal will improve symptoms and quality of life for these individuals. we propose to carry out a comprehensive battery of clinical, laboratory, microbiological and psychometric evaluations before and after lactulose withdrawal. we will closely follow changes in cognitive function and re-institute lactulose therapy at the first sign of clinical deterioration. through multivariate analysis we propose to develop a model to discriminate between treatment dependent and treatment independent patients.

Eligibility criteria:
inclusion criteria: * diagnosis of hepatic cirrhosis based on biopsy, clinical and/or radiological findings. * stable he (chronic): on daily lactulose for more than 6 months without hospitalization for he within 3 months of enrollment. * treated with lactulose on a daily basis, with restoration of mental status to baseline. * lives with an adult individual who is willing to serve as a full-time caregiver. * able and willing to give informed consent. exclusion criteria: * use of antibiotics, including rifaximin. * patient without an adult caregiver. * pre-existing focal neurological deficits, seizures or other indication of structural neurological disorder. * actively abusing illicit drugs or alcohol.
defining the prep care continuum among recently incarcerated men at high-risk for hiv infection

Conditions: HIV Infections; Sexually Transmitted Diseases

Summary: background: several major studies have demonstrated the success of truvada as pre-exposure prophylaxis (prep) in preventing hiv infection.the cdc guidelines recommend prep for people who are at elevated risk of hiv including men who have sex with men (msm) and people who use injection drugs. people who are incarcerated bear a disproportionate of disease burden, including hiv. furthermore, men who have been involved with the criminal justice system are more likely to engage in risky behaviors following their release, including condomless sex with partners of unknown serostatus, and injection drug use. the incarceration setting provides a place to engage men who may be at risk of hiv after they are released. following release, community clinics, including the std clinic at the miriam hospital (tmh) immunology center, that perform routine testing for hiv and other sexually transmitted diseases (stds) may be ideal settings to engage vulnerable populations in care, including prep. despite the demonstrated clinical efficacy of prep in reducing hiv transmissions, few clinical programs have piloted the use of prep in real-world settings, particularly criminal justice settings. furthermore, studies demonstrate numerous challenges to prep uptake and adherence, including a lack of access or discontinuing care. engaging at risk men in prep care before they leave prison and potentially lost to care during the transition may increase uptake, adherence, and retention. objective: this study protocol will evaluate a clinical program that aims to prevent new hiv infections among recently-incarcerated men using a once daily dosing of tenofovir/emtricitabine (truvada) as pre-exposure prophylaxis (prep). this protocol presents an overview of the clinical program, which uses standard-of-care clinical practices and centers for disease control and prevention (cdc) guidelines for prescribing and monitoring prep. male inmates at the rhode island department of corrections (ridoc) will be screened for hiv risk and, if eligible and interested, will be prescribed and given a one-month supply of prep shortly before their release, and receive follow up care at the miriam hospital (tmh) immunology center following their release.


Eligibility criteria:
inclusion criteria: * current men committed at the ridoc (aged 18 and above); hiv negative; meet cdc indications for prep use (based on risk criteria before they were sentenced); interested in taking prep; and are able to voluntarily consent to be treated will be included exclusion criteria: * individuals who are younger than 18 years old; are hiv positive, hepatitis b virus positive or have a crcl\<60; or unable to provide voluntary consent will be excluded.
a multicenter randomized placebo-controlled double-blind study to assess efficacy and safety of glutamine and creatine monohydrate in duchenne muscular dystrophy (dmd)

Conditions: Muscular Dystrophy, Duchenne

Summary: to establish a collaborative group of clinical trial centers, with standardized equipment and protocols, able to conduct both drug and gene therapy trials in dmd. to evaluate the therapeutic effect of glutamine and creatine monohydrate on muscle strength in children with dmd. to validate the use of qmt (quantitative muscle strength testing) and gait analysis in children with dmd as reliable tools to quantify muscle strength, monitor disease progression and assess therapeutic response.

duchenne muscular dystrophy (dmd) is the most common lethal inherited disorder worldwide. despite the exponential increase in our understanding of the disorder since the discovery and characterization of the causative gene and its product dystrophin in 1987, current therapeutic management remains largely supportive. awaiting a final genetic cure to be available in the future, further investments in developing better drug therapies for dmd remain important. not only because the uniform use of prednisone (the only drug proven to be beneficial) is hampered by potential adverse effects, but also because it may very well be the case that ultimately a combination of both gene and drug therapy will be needed to cure duchenne children. here, we test two compounds that have shown promise in a 45-drug screen in the mdx mouse model of duchenne dystrophy. the effect of glutamine (0.6/kg/day) and creatine monohydrate (5g/day) on muscle strength will be evaluated in a multi-center randomized double-blind placebo-controlled 3-arm study. ambulant children aged 5-10 years with an established dmd diagnosis will be studied. patients will undergo 2 screening evaluations within 2 weeks. patients will be randomized into treatment groups on the second screening visits, followed by a 6-month treatment period. during the treatment period, patients will be evaluated at monthly intervals. the primary endpoints are percentage change in average muscle strength score and qmt performance for specific muscle groups. secondary endpoints include timed function tests, functional grades for arms and legs, and pulmonary function tests.

Eligibility criteria:
ambulant children age 5-10 years with an established diagnosis of duchenne muscular dystrophy
individualized exercise oncology program for newly diagnosed breast cancer patients

Conditions: Breast Cancer

Summary: to test the effect of an individualized exercise oncology program on healthcare utilization, 30-day hospital readmission, pain, and cancer treatment tolerance.


Eligibility criteria:
inclusion criteria: * female; determined from electronic medical record * initial stage 0, 1 or 2 breast cancer diagnosis within the past 12 weeks determined from electronic medical record * age 30-80; determined from electronic medical record * physician clearance to participate in exercise exclusion criteria: * participation in supervised physical exercise within 6 months prior to study enrollment * currently pregnant or planning to become pregnant * non-english speaking * unable to make own medical decisions and/or to follow verbal instructions
pilot study : new sensors to monitor apnea during sedation

Conditions: Sleep Apnea, Obstructive; Anesthesia

Summary: evaluation of a mandibular and abdominal motion detection sensor (jawac) to prevent apnea during sedation with propofol in tci mode

in 2016 , monitoring of propofol sedation , currently recommended by the american society of anaesthesiology and european companies includes among others, a pulse oximeter (spo2) and a continuous measurement of co2 exhaled by an appropriate device (capnoline). this monitoring does not allow to anticipate the occurrence of obstructive apnea . the anticipation of the occurrence of apnea or airway obstruction using this type of monitoring could allow the anesthesiologist to act earlier on the titration of propofol and maintaining the airway. this would avoid the side effects associated with hypoxemia and hypercapnia and therefore further improve patient safety . this pilot study tests the jawac system to detect those apneas. this is an interventional diagnostic study on the jawac monitoring system validation in a prospective cohort of patients undergoing sedation in order to provoke sleep apnea. indeed , sedation technique is already used with propofol during snoring provocation tests in patients at risk for sleep apnea.

Eligibility criteria:
inclusion criteria: * any adult patient scheduled for a sleep apnea provocation test under sedation by propofol * hospital erasme during the period of the study. exclusion criteria: 1. patient refusal 2. patient age: 18 years and under 80 years 3. intervention earlier in the mandible or thorax 4. a history of facial burn 5. allergy tape

Keywords: propofol deep sedation anoxia hypercapnia
a proof of concept study of the efficacy and safety of oral lat8881 in acute migraine

Conditions: Acute Migraine

Summary: this is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral lat8881 in acute migraine, with or without aura.

subjects enrolled in the study will be randomised to receive investigational medicinal product (lat8881 60 mg or placebo), to be taken at the onset (within one hour from the onset of pain) of a migraine headache of moderate to severe intensity \[numeric rating scale greater than 4\]. rescue medication should not be taken until at least 2 hours post dose. subjects will be given a single dose of either active or placebo, to treat one migraine headache. after treatment of one migraine headache (or a maximum 28 days) the subject will return to the clinic for re-evaluation and crossover to the second treatment. after treatment of one migraine headache in the second treatment period or a maximum of 28 days from commencement of the second treatment period, the subject will return to the clinic for re-evaluation. an end of study visit (telephone) will occur 7 days after the end of the second treatment period.

Eligibility criteria:
inclusion criteria: 1. males or females aged 18 to 75 years at the time of consent 2. diagnosis of episodic migraine headache at least 12 months ago with or without aura as defined in international classification of headache-3 3. onset of migraine headache before age 50 4. medical history of 2 - 8 migraine headache attacks per month for the previous 12 months; ≥ 75% of attacks progress to moderate or severe pain within 2 hours (ie, rapidly-escalating) 5. minimum 48 hours on average between migraine headache attacks 6. acute headache medication on ≤ 14 days/month in the 3 months prior to screening 7. willing and able to comply with all study procedures including completion of a headache diary and a migraine diary on the day of a migraine headache exclusion criteria: 1. unable to distinguish migraine from other primary headache conditions 2. average of 15 or more headache (migraine or nonmigraine) days per month or history of more than 25% of headaches occurring at time of wakening (wake up headaches) 3. history of aura lasting more than 60 minutes 4. history of vomiting within 2 hours of onset of a migraine headache in more than 25% of migraine headaches 5. medication overuse headache, defined as: 1. use of opioids, triptans or ergot alkaloids or any combination of these medications for treatment of headaches 10 or more days per month during the 90 days prior to screening or 2. non-steroidal anti-inflammatory drugs (nsaids) or simple analgesics for treatment of headaches on more than 14 days per month during the 90 days prior to screening 6. recent (3 years) history of frequent or chronic hemiplegic/ basilar migraine, tension headache, retinal migraine, ophthalmoplegic migraine as per ichd classification, or treatment resistant atypical migraine 7. hospital admission for status intractable migraine or medication overuse headache within 6 months of screening
regulation of lipid metabolism in guangzhou individuals with dyslipidemia by red yeast rice, phytosterol esters and lycopene

Conditions: Hypercholesterolemia

Summary: the objective of this study is to evaluate the effect of using red yeast rice, phytosterol esters and lycopene in combination for 12 weeks on improving the glycolipid metabolism of guangzhou individuals with dyslipidemia. our hypothesis is that when compared with placebo, red yeast rice, phytosterol esters and lycopene together as supplements would lead to greater improvements in lipid metabolism (including lipid profiles and parameters ) in participants after 12 weeks.


Eligibility criteria:
inclusion criteria: 1. age: 30-50 years old. 2. non-obese individuals: 18.5 ≤ bmi \< 28. 3. total cholesterol levels ranging from marginal increase to increase: 6.2\> tc ≥ 5.2 mmol/l (200 mg/dl). exclusion criteria: 1. currently being pregnant or breast-feeding or planning to become pregnant. 2. having severe complications of diabetes mellitus as well as any forms of cardiovascular diseases, tumor, liver diseases and kidney diseases. 3. history (past 3 months) of intake of lipid-lowering or anti-diabetic health care products. 4. having hemorrhagic diathesis (high bleeding tendencies) or currently taking aspirin. 5. unwilling/unable to draw blood due to physical/personal reasons. 6. history (past 1 month) of surgery. 7. history (past 1 month) of large amounts of oral or intravenous treatment of glucocorticoids (such as prednisone, methylprednisone, betamethasone, beclomethasone propionate, dubossone, prednisone, hydrocodesone, dexamethasone). 8. history (past 2 weeks) of taking supplements containing red yeast rice, phytosterol ester or lycopene. 9. unqualified outcomes of safety measures at baseline.
the effect of niv on qol and exercise capacity in a copd exercise rehabilitation program

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this trial hopes to demonstrate the effect of 4 weeks of outpatient exercise rehabilitation on copd patients. in particular the effect on: * the amount of daily physical activity * quality of life * the 6-minute walk distance * time to exacerbation and compare it to the effect of 4 weeks of outpatients rehabilitation with noninvasive ventilation as an adjunct therapy.


Eligibility criteria:
inclusion criteria: * diagnosis of copd iii+iv * age \>18 years * former niv treatment for at least 6 weeks with a positive end-expiratory pressure of at least 4 cmh2o and a pressure support of 8 cmh2o or higher exclusion criteria: * pulmonary exacerbation requiring antibiotic treatment or hospitalization during the last 6 weeks * non-pulmonary exercise impairment (amputation, severe heart disease, etc) * any disease that precludes exercise training * inability to understand the patient information * substance abuse * oxygen requirement of more than 6l o2/min during exercise
oncologic risk of rectal preservation against medical advice after chemoradiotherapy for rectal cancer

Conditions: Rectal Cancer; Chemoradiation

Summary: though refusal of radical surgery was often happened in rectal cancer patient after neoadjuvant chemoradiotherapy, little is currently known about the actual oncologic outcome of it. thus the investigators designed this study to compare the oncologic outcome of unintended rectal preservation with intended rectal preservation by surgeon.

the investigators identified patients whose organ were preserved by non-operative management or local excision after neoadjuvant chemoradiotherapy for mid to low rectal cancer. then, the patients were categorized into two groups according to the agreement on omitting radical surgery (rectal preservation). when treatment decision was agreed by their surgeon, the patients were categorized as intended rectal preservation. when there was disagreement by surgeon on rectal preservation, then the patients categorized as unintended rectal preservation. oncologic outcome was compared between two groups.

Eligibility criteria:
inclusion criteria: * biopsy proven rectal cancer (anal verge ≤ 10cm) * neoadjuvant radiotherapy or chemoradiotherapy * no radical surgery after neoadjuvant therapy exclusion criteria: * other malignant disease * other fatel disease * incompletion of half of radiotherapy course * metastasis on initial presentation

Keywords: organ preservation oncologic outcome